Then, we report a complex structure of DCLK1 kinase domain with the most potent inhibitor ruxolitinib, which has been originally developed as a Janus kinases (JAK1 and JAK2) inhibitor for treatment of myelofibrosis [29]. Here, JAK1 is linked to myelofibrosis.